7 completed. 6 Phase 1, 2 Phase 2.
By phase and status
Follow samatasvir: new trials by email Literature Review of samatasvir trials Research Report on samatasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
IDX719 - Hepatitis C, Chronic | Phase 1 | Completed | 36 | 2013-08-01 | 2016-01-26 |
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
IDX719, Simeprevir, TMC647055 - Hepatitis C, Chronic | Phase 1 | Completed | 34 | 2013-05-01 | 2016-01-26 |
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
Samatasvir, Simeprevir, Ribavirin (RBV) - Chronic Hepatitis C Virus | Phase 2 | Completed | 143 | 2013-03-01 | 2015-04-23 |
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
Samatasvir, Omeprazole, Ritonavir - Chronic Hepatitis C Infection | Phase 1 | Completed | 24 | 2013-02-01 | 2016-01-22 |
Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)
IDX719, Simeprevir - Chronic Hepatitis C Infection | Phase 1 | Completed | 42 | 2013-01-01 | 2016-01-26 |
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
IDX719, Placebo - Hepatitis C, Chronic | Phase 1 / Phase 2 | Completed | 130 | 2012-01-01 | 2015-04-27 |
A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)
Samatasvir tablet, Samatasvir capsule - Hepatitis C | Phase 1 | Completed | 12 | 2011-04-01 | 2016-01-26 |
Conditions studied
Hepatitis C (7) · Hepatitis C, Chronic (4)
Sponsors
Merck Sharp & Dohme LLC (7)
Results publications
PMID 24434503